

MNNR

MORBIDITY AND MORTALITY WEEKLY REPORT

- Following Ingestion of Raw Carp Gallbladders — Maryland and Pennsylvania, 1991 and 1994
- 567 Chancroid Detected by Polymerase Chain Reaction — Jackson, Mississippi, 1994–1995
- 574 Update: Recommendations to Prevent Hepatitis B Virus Transmission — United States
- 575 Notice to Readers

Acute Hepatitis and Renal Failure Following Ingestion of Raw Carp Gallbladders — Maryland and Pennsylvania, 1991 and 1994

In some cultures, eating gallbladders from certain species of snakes, birds, or fish is believed to improve health. A syndrome of acute hepatitis and renal failure following the ingestion of raw carp gallbladders has been described previously among persons living in Asia (1–4). This report summarizes two cases of this syndrome that occurred in residents of Pennsylvania who had eaten the raw bile and gallbladders of carp caught in Maryland.

Patient 1. On July 11, 1991, a 59-year-old man who had immigrated from Korea ate the uncooked gallbladder of a carp he had caught in Maryland from a tributary of the Susquehanna River. Six hours after eating the gallbladder, he developed diarrhea and abdominal pain. On July 14, he was admitted to a hospital with mild jaundice and persistent nausea and vomiting. Laboratory testing revealed elevated levels of serum creatinine (10 mg/dL [normal: 0.7–1.5 mg/dL]), total bilirubin (3.5 mg/dL [normal: 0.1–1.2 mg/dL]), and transaminases (aspartate aminotransferase [AST] 171 U/L [normal: <54 U/L] and alanine aminotransferase [ALT] 1043 U/L [normal: <52 U/L]). Renal ultrasound detected no evidence of hydronephrosis. Despite transient progression of his renal failure, the patient did not require dialysis. He was discharged from the hospital after 6 days with normal urine output, a serum creatinine of 4 mg/dL and normal liver function.

Patient 2. On October 30, 1994, a 41-year-old man who had immigrated from Cambodia ate the raw gallbladders from three carp he had caught at a reservoir near Cowonigo, Maryland. Two hours after eating the gallbladders, he developed transient right upper quadrant abdominal pain, nausea, vomiting, and diarrhea. On November 3, he consulted his physician because of recurrent nausea, abdominal pain, and decreased urinary output. Laboratory findings were consistent with acute hepatitis (AST 1032 U/L, ALT 2028 U/L, and total bilirubin 4.8 mg/dL) and acute renal failure (serum creatinine 6.0 mg/dL). Abdominal ultrasound revealed normal-sized kidneys; there was no evidence of urinary or biliary tract obstruction. The patient was hospitalized for hemodialysis when, 5 days after his exposure, his serum creatinine increased to 12.6 mg/dL. The patient's renal and hepatic function gradually improved, and he was discharged on November 16 with a serum creatinine of 8 mg/dL and markedly improved liver function.

Acute Hepatitis and Renal Failure - Continued

Reported by: SJ Goldstein, MD, RM Raja, MD, M Kramer, MD, W Hirsch, MD, Div of Nephrology, Albert Einstein Medical Center, Philadelphia, Pennsylvania. EB May, PhD, Div of Fisheries, Maryland Dept of Natural Resources, Oxford. Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC.

Editorial Note: Despite the widespread use of basic public health food safety and hygiene measures, clinicians and public health practitioners have encountered an increasing diversity of foodborne illnesses. Factors contributing to this trend include changes in the technology of food production, greater importation of food from other

countries, and a diversification of food preparation and eating habits.

Although acute hepatitis and renal failure following ingestion of raw carp gall-bladders have not been reported previously in persons in the United States, such cases have been recognized in persons in Taiwan (1,2), Hong Kong (3), and South Korea (4). Clinical manifestations of this syndrome include acute gastrointestinal symptoms followed several days later by jaundice and oliguria. Histologic studies of kidney and liver tissue specimens from patients demonstrate acute tubular necrosis and focal hepatitis (4). Although the bile component(s) responsible for this syndrome have not been characterized fully (5), cyprinol, a C₂₇ alcohol found in the bile of cyprinid fish, may have a direct toxic affect on the kidneys (1). No specific treatment has been identified; renal and hepatic impairment generally resolve within 3 weeks with supportive care.

Five species of fish belonging to the order Cypriniformes have been associated with bile-induced hepatitis and renal failure (4). Two of these species are found in the United States: the common carp (Cyprinus carpio), which is abundant and widely distributed in North America, and the grass carp (Ctenopharyngodon idellus), which has been introduced in many areas in the eastern United States (J. Sheferland, Chesapeake Bay Field Station, U.S. Fish and Wildlife Service, personal communication, 1995). Because they can be caught without limit, carp are an inexpensive food source used extensively by some populations.

The syndrome of bile-induced hepatitis and renal failure described in this report, in addition to previous reports of foodborne illnesses (e.g., trichinosis [6] and mush-room poisoning [7]), suggest that clinicians should be aware of eating habits and food exposures that may pose a risk for their patients. The cases described in this report also underscore the importance of obtaining careful food histories from patients, including those whose illness may not initially appear to be food-related.

References

- Chen WY, Yen TS, Cheng JT, Hsieh BS, Hsu HC. Acute renal failure due to ingestion of raw bile of Grass Carp (Ctenopharyngodon idellus). J Formosan Med Assoc 1976;75:149–57.
- Lim PS, Lin JL, Hu SA, Huang CC. Acute renal failure due to ingestion of the gallbladder of grass carp: report of 3 cases with review of the literature. Renal Failure 1993;15:639–44.
- Chan DWS, Yeung CK, Chan MK. Acute renal failure after eating raw fish gall bladder. BMJ 1985;290:897.
- Park SK, Kim DG, Kang SK, et al. Toxic acute renal failure and hepatitis after ingestion of raw carp bile. Nephron 1990;56:188–93.
- Yip LL, Chow CL, Yung KH, Chiu KW. Toxic material from the gallbladder of the grass carp (Ctenopharyngodon idellus). Toxicon 1981;19:567–9.
- 6. CDC. Trichinella spiralis infection-United States, 1990. MMWR 1991;40:57-60.
- 7. CDC. Mushroom poisoning among Laotian refugees-1981. MMWR 1982;31:287-8.

Chancroid Detected by Polymerase Chain Reaction — Jackson, Mississippi, 1994–1995

Chancroid is a sexually transmitted disease (STD) caused by infection with *Haemophilus ducreyi* and is characterized by genital ulceration. Chancroid is underreported in the United States (1), reflecting, in part, difficulties in diagnosis because of clinical similarities between chancroid and other ulcerative STDs. In addition, laboratory confirmation by culture is 53%–84% sensitive and often is unavailable in clinical settings (2). In September 1994, clinicians at the District V STD clinic of the Mississippi State Department of Health (MSDH) in Jackson reported examining patients with genital ulcers characteristic of chancroid but lacked capacity to confirm the diagnosis. To determine the cause of the ulcers, MSDH, in conjunction with CDC, conducted an investigation of all patients with genital ulcers examined at the Jackson STD clinic during October 20, 1994–February 1, 1995. This report summarizes the findings of the investigation.

Swab specimens were obtained from the genital ulcers of all patients examined at the Jackson STD clinic. Specimens were tested at an independent laboratory using a research prototype multiplex polymerase chain reaction (PCR) assay that can amplify and subsequently detect DNA from *H. ducreyi, Treponema pallidum*, and herpes simplex virus (HSV) from a single swab specimen (3). All positive PCR results were confirmed by additional PCR research assays that amplify and detect different gene sequences. Serologic testing included standard human immunodeficiency virus (HIV)

testing at the Mississippi State Public Health Laboratory.

During October 20, 1994–February 1, 1995, a total of 81 patients with genital ulcers were examined at the clinic. Of these, 66 (82%) were male. The median age was 33 years (range: 16 years–81 years). Of the 81 patients, 41 (51%) had *H. ducreyi* infection confirmed by PCR. For 33 patients, DNA sequences from *H. ducreyi* only were identified; for seven, DNA sequences from *H. ducreyi* and one other organism were identified; and for one, DNA sequences from *H. ducreyi* and two other organisms were identified (Table 1, page 573). For 12 (15%) patients, no etiology was identified.


Of 79 patients tested for HIV antibody, eight (10%) were positive.

Because this investigation confirmed a high prevalence of chancroid among persons with genital ulcers, MSDH now recommends presumptive treatment for both syphilis and chancroid for all patients in Jackson with nonherpetic genital ulcers and for their sex partners. In March 1995, MSDH initiated statewide surveillance for genital ulcers by requesting 25 public clinics and emergency departments to record information about every patient with a genital ulcer. In addition, a case-control study is under way in Jackson to assess risk factors for chancroid, syphilis, and genital herpes. MSDH plans to examine risk and health-seeking behaviors of persons with genital ulcers and to provide additional HIV-prevention services to these persons.

Reported by: RM Webb, MD, R Hotchkiss, MD, Div of Community Health Svcs, M Currier, MD, State Epidemiologist, Mississippi State Dept of Health; D Grillo, MD, P Byers, MD, D Jones, V Grant, District V Health Dept, Jackson. JB Weiss, PhD, KA Orle, MS, Roche Molecular Systems, Alameda, California. Epidemiology and Surveillance Br, Behavioral Research and Intervention Br, and Program Development and Support Br, Div of Sexually Transmitted Disease Prevention, National Center for Prevention Svcs; Treponemal Pathogenesis and Immunology Br, Div of Sexually Transmitted Diseases Laboratory Research, National Center for Infectious Diseases,

CDC.

FIGURE I. Notifiable disease reports, comparison of 4-week totals ending July 29, 1995, with historical data - United States



Beyond Historical Limits

*The large apparent decrease in the number of reported cases of measles (total) reflects dramatic fluctuations in the historical baseline.

[†]Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — cases of specified notifiable diseases, United States, cumulative, week ending July 29, 1995 (30th Week)

	Cum. 1995		Cum. 1995
Anthrax Brucellosis Cholera Congenital rubella syndrome Diphtheria* Haemophilus Influenzas* Hansen Diaeese Plague Poliornyelitis, Parahytic	51 8 4 718 81 81	Paittacoais Rabiss, human Rocky Mountain Spotted Fever Syphilis, congenital, age < 1 year [§] Tetanua Toxic shock syndrome Trichinosis Typhoid fever	39 1 224 132 13 113 23 171

case previously reported in 1995 had onset of illness in October 1994. It will now be included in 1994 data. 87 cases of known age, 174 (25%) were reported among children less than 5 years of age. ated questerly from reports to the Division of Sexually Transmitted Diseases and HIV Prevention, Nation ention Sarvices. This total through first querier 1995.

TABLE II. Cases of selected notifiable diseases, United States, weeks ending July 29, 1995, and July 30, 1994 (30th Week)

Reporting Area	AIDS*	Gener	rhea	A		В		C/NA	,NB	Legionellosi	
	Cum. 1995	Cum. 1995	Curn. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994
UNITED STATES	35,614	201,822	226,303	14,951	13,237	5,665	6,595	2,477	2,357	721	826
NEW ENGLAND	1,797	2,591	4,552	151	182	119	224	68	91	14	18
Maine	71	44	54	17	17	6	10	-		4	2
N.H.	56	71	63	6	12	13	16	9	7	1	
Vt. Mass.	15 812	30 1,558	16	62	75	45	6	1	6		:
R.I.	137	288	1,705 272	18	14	8	137	58	62 16	8	8
Conn.	706	600	2,442	44	00	46	50		10	N	N
MID. ATLANTIC	9,135	21,246	25,217	891	967	672	852	229	280	108	128
Upstate N.Y.	1,133	3,846	5,661	228	369	220	231	120	128	30	26
N.Y. City	4,481	7,375	9,353	408	329	190	180	1	1	1	
N.J.	2,225	2,224	2,982	129	182	155	225	86	125	15	19
Pa.	1,296	7,801	7,221	126	87	107	216	22	26	62	83
E.N. CENTRAL	2,897	42,915	45,517	1,738	1,258	562	690	161	206	190	243
Ohio	607	13,245	13,151	1,106	414	73	102	6	14	94	111
Ind.	261 1,284	4,523 11,653	4,800 13,525	92 217	220 331	131	127	33	8 56	13	24 23
Mich.	572	10,202	9,837	215	154	233	229	121	128	21	51
Wis.	173	3,292	4,204	108	139	31	49		140	18	34
W.N. CENTRAL	867	10,887	12,643	1,016	622	341	378	60	53	72	60
Minn.	204	1,601	1,821	110	123	32	40	2	11	12	2
lowa	44	798	719	44	29	26	17	7	7	14	25
Mo.	346	6.246	7,183	719	282	239	280	37	12	41	19
N. Dak.	5	16	25	18	3	4		4	1	4	4
S. Dak.	9	100	110	25	17	2		1		-	
Nebr.	71	491	794	31	90	18	20	5	9	8	8
Kans.	188	1,635	1,991	69	78	20	21	4	13	5	2
S. ATLANTIC	9,055	58,452	60,215	707	659	836	1,290	188	287	130	191
Del.	165	1,206	1,067	***	16	2	9	1	- 1	1	
Md. D.C.	1,313 579	7,193 2,595	11,084 4,212	124	96 15	153	206 30	2	17	23	50
Va.	645	5,711	7,290	106	91	59	71	9	18	8	5
W. Ve.	44	471	416	11	7	29	23	28	21	3	1
N.C.	490	13,808	15,382	68	69	178	166	33	37	23	13
S.C.	449	6,709	7,342	25	25	33	22	15	3	21	9
Ga.	1,090	9,134	U	54	23	63	496	15	159	23	81
Fla.	4,280	11,625	13,422	295	315	308	267	87	31	24	27
E.S. CENTRAL	1,109	25,007	25,933	930	309	532	650	650	509	24	64
Ky.	155	2,760	2,710	26	102	41	57 548	13	17	3	8
Tenn. Ala.	437 298	7,712	8,328 8,904	808 53	125 50	67	45	635 2	8	15	32
Miss.	219	4,084	5,991	43	32					1	15
W.S. CENTRAL	3,137	20,840	27,640	1,838	1,717	858	663	379	158	8	23
Ark.	137	2,069	4,008	227	48	29	14	3/9	4	1	4
La.	502	6.925	7.237	53	86	110	105	101	82	2	6
Okla.	154	1,382	2,781	435	153	271	72	248	37	3	9
Tex.	2,344	10,464	13,614	1,123	1,430	448	472	27	35	2	4
MOUNTAIN	1,119	5,031	5,734	2,345	2,556	491	368	268	257	82	56
Mont.	9	40	44	60	15	16	15	10	5	4	14
Idaho	26	68	47	215	192	56	58	33	56	2 6	1
Wyo.	6	28	47	79	13	16	14	119	80	34	13
Colo. N. Mex.	372 107	1,686 590	1,908 577	307 485	305 648	72 185	122	39 34	37	3	2
Ariz.	299	1,735	1,968	656	970	78	31	17	12	7	- 2
Utah	89	131	172	487	264	53	36	8	11	13	
Nev.	231	753	973	58	149	15	32	8	12	13	16
PACIFIC	6,498	14,853	18,852	5,335	4,967	1,254	1,480	474	516	93	40
Wash.	495	1,432	1,897	430	656	104	133	122	145	12	8
Oreg.	223	212	559	1,077	558	52	83	28	23	*	
Calif.	5,594	12,435	15,641	3,694	3,585	1,080	1,230	314	344	76	30
Alaska Hawaii	46 140	409 365	525 430	29 105	137	12	10 24	1	i	5	1
	140				-		24		•		
Guam PR.	1,514	51 316	75 312	2	13 36	453	193	217	98	1	1
P.R.	1,514	316	12	60	38	453	193	217	1		
Amer. Sampa	21	14	18	5	5			-			
C.N.M.I.		20	31	15	4	7	1		-		

N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands *Updated monthly to the Division of HIV/AIDS Prevention, National Center for Prevention Services, last update June 29, 1995.

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending July 29, 1995, and July 30, 1994 (30th Week)

		200					Measte	es (Rube	rote)		Maria	pococcal		
Reporting Area	Lyn		Mala		Indigu	enous	impo	orted*		otal	Infec	ctions	Mun	
	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	1995	Cum. 1995	1995	Cum. 1996	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994	Cum. 1995	Cum. 1994
UNITED STATES	3,357	5,439	589	551	3	209	1	10	219	818	1,945	1,782	510	829
NEW ENGLAND	949	1,238	26	39	3	7			7	24	94	77	9	15
Maine	4	6	3	2	:					4	6	13	4	3
N.H. Vt.	15	13	1	3	*	*	*		*	1 3	17	7 2	1	4
Mass.	94	71	9	18	-	2			2	7	34	34	2	1
R.L.	153	174	2	5	3	5	*		5	6				1
Conn.	677	968	11	10	-	-	*	*		3	31	21	2	6
MID. ATLANTIC Upstate N.Y.	1,847 940	3,246	148 35	92 27	*	4	*	2	6	209 15	235	186 61	69 19	78
N.Y. City	66	8	68	29	:	2		2	4	13	79 28	24	5	23
N.J.	358	634	32	18		2			2	173	61	40	6	13
Pa.	485	390	13	18		-	*			8	67	61	39	40
E.N. CENTRAL	43	358	69	59		7		2	9	102	256	259	86	147
Ohio Ind.	28	22 10	12	8		1	*		1	17	85 39	74 37	26	41
III.	3	16	32	26	-			1	i	56	71	89	26	63
Mich.	5	5	13	14		4		i	5	25	51	32	31	31
Wis.		305	7	2	*	2			2	3	10	27		6
W.N. CENTRAL Minn.	43	94 22	14	27		2	:		2	169	119 18	116	31	43
lows	6	4	1	4	-					7	18 23	11	8	10
Mo.	20	63	4	10		i			1	159	45	57	17	27
N. Dak.			1	1		:					1	1		2
S. Dak. Nebr.	i	2	3	3			*			2	5	7 9	4	i
Neor. Kans.	16	3	1	1		i	:		i	1	10	18	4	1
S. ATLANTIC	334	368	123	103		10	1	1	11	52	352	264	80	133
Dal.	7	44	1	3							5	4		
Md.	230	128	32	43		-	1	1	1	3	28	22	20	36
D.C. Va.	30	3 46		12			-			2	41	3 50	15	29
W. Va.	16	10	1							37	7	11		3
N.C.	26	43	11	2						3	53	41	16	33
S.C. Ge.	10	82		17		2	-		2	2	47 74	12	7	6
Ge. Fis.	7	82		16		8			8	5	94	61	14	18
E.S. CENTRAL	22	25	11	20						28	122	134		15
Ky.	4	15	1	7	*						40	29		*
Tenn. Ala.	15	7 3	4	7	*	*	*			28	35 28	25 51	i	5
Ala. Miss.	2	3		1				1			28 19	51 29		7
W.S. CENTRAL	62	62	16	24	-	19	-		19	16	241	216		169
Ark.	5	3	3	2		2		1	2	1	20	35	2	5
Lo.	1		. 1	4	*	17			17	i	35	28	8	20
Okia. Tex.	25 31	32 27		16		*				14	23 163			121
MOUNTAIN	7					49		1			163			34
Mont.	7		. 3		- 1	49	2	1	50	150	2	4	1	
Idaho		1	1	2							6	15	2	7
Wyo.	4	1		1	*						5	5		1
Colo. N. Mex.	1					30	-	i	31		36 28			2 N
Ariz.	1		. 6	1		10	-	1	10	1	46	43	2	3
Utah		1	4	4						130	11	16	11	12
Nev.	1					1			1	9	7	7	6	9
PACIFIC Wash	50					111		4						195
Wash. Oreg.	4 3	5	13			13	:	2	15	3	68		10 N	14 N
Calif.	43		119	129		97		1			248	245	141	169
Alaska			. 1							5	6	2		2
Hawaii			. 9	10				1	1 1					10
Guam					U		U			228			3	4 2
P.R. V.L			. 1	3	Ü	11	ú		- 11	11	13	5		3
Amer. Samoa														2 2
C.N.M.I.			. 1	1 1	U		U			. 29				

^{*}For imported messles, cases include only those resulting from importation from other countries.

N: Not notifiable U: Unevailable < no reported cases

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending July 29, 1995, and July 30, 1994 (30th Week)

Reporting Area		Pertusais			Rubella		Syph (Prima Second	ry & dary)	Tuberca	dosis	Rabies, Animal		
	1995	Cum. 1995	Cum. 1994	1995	Cum. 1995	Cum. 1994	Cum. 1985	Cum. 1994	Cum. 1995	Cum. 1994	Curn. 1996	Cum. 1994	
UNITED STATES	84	1,633	2,052	3	91	198	8,749	12,367	10,537	12,340	4,092	4,242	
NEW ENGLAND	7	235	221		22	126	99	134	258	259	935	1,065	
Maine		21	2		1		2	4	12		21		
N.H.		21	43		1	*	1	3	9	13	101	105	
Vt. Mass.	5	29 153	28 125	*	6	123	35	54	120	120	118 306	92	
R.I.	1	1	5			2	1	11	129 27	130	178	405	
Conn.		10	18		14	1	60	62	78	81	211	458	
MID. ATLANTIC	1	143	321	1	7	6	513	809	2,200	2,405	808	1,045	
Upstate N.Y.	i	73	124	i	4	5	43	97	245	319	312	771	
N.Y. City		23	67		3	-	243	358	1,180	1,461			
N.J.	*	5	10	-		1	106	131	416	436	224	166	
Pa.		42	120				121	223	359	189	272	108	
E.N. CENTRAL	3	150	331	-	2	9	1,495	1,793	1,042	1,182	33	32	
Ohio		52	96				522	670	161	188	4	:	
Ind.	3	13	39 67			1	152 554	142	38 590	98 591	5	7	
Mich.		35	26		2	8	170	173	218	269	18	9	
Wis.	*	12	103		-		97	199	35	36	3	6	
W.N. CENTRAL	3	87	86	-		2	481	720	328	305	194	132	
Minn.		28	39				28	25	73	64	6	14	
lowa	*	5	6			*	28	33	41	28	70	54	
Mo.	-	18	24	*		2	393	619	131	141	19	11	
N. Dak. S. Dak.		6 7	4	-			-	1	13	16	23 49	22	
Nebr.	1	5	5				3	11	10	8	40	22	
Kans.	2	18	7				9	30	58	42	27	25	
S. ATLANTIC	26	185	203	1	25	13	2,193	3,168	1,980	2.293	1,252	1,173	
Del.	1	8	1				8	18	12	26	33	31	
Md.		16	57	*			129	147	238	180	247	337	
D.C.	1	4	4		*	-	70	142	62	68	10	2	
Va. W. Va.	1	10	17				336	434	136	201	245 70	224	
N.C.	5	73	52				660	1,011	241	51 259	282	101	
S.C.	1	16	10		1		341	442	190	217	81	109	
Ga.	6	13	20		1	1	428	495	307	440	164	234	
Fla.	11	45	40	1	23	12	213	471	745	851	120	89	
E.S. CENTRAL	3	80	103				2,256	2,181	652	853	144	116	
Ky.			54	*		-	119	124	53	193	14	10	
Tenn.	1	50	18				474	582	255	265	49	34	
Ala. Miss.	2	30	20 11	N	N	N	362 1,301	397 1,078	218 126	244 151	78	69	
	-												
W.S. CENTRAL Ark.	3	107	66		6	12	1,253	2,821	1,300	1,586 146	491 21	432	
La.	1	10	9				624	1,041	6	7	23	47	
Okla.		22	21			4	47	98	124	148	25	24	
Tiese.	2	75	24		6	8	482	1,382	1,078	1,265	422	346	
MOUNTAIN	4	306	260		4	4	168	184	340	307	86	84	
Mont.		3	3				4	2	10	9	29	10	
Idaho	-	77	24	-				1	9	11	1	- 2	
Wyo.		1	143	-			4	91	22	33	20	14	
Colo. N. Mex.	2	23 53	143				80 29	18	50	43	3		
Ariz.	-	128	59		3		19	37	168	124	25	4	
Utah		16	13	-	1	3	4	9	19	23	7		
Nev.	-	5	2			1	28	26	61	60	1	:	
PACIFIC	34	340	461	1	25	26	311	557	2,437	3,170	149	16	
Wash.	2	78	56		1		9	25	158	155	2		
Oreg.	1	11	61	-	1	3	6	20	25	90	***	-	
Calif.	27	216	334	1	20	20	295	506	2,116	2,734	143	12	
Alaska Hawaii	4	35	10		3	3	1	3	93	154		3	
		30	2	U		1	3	3	33	45			
Guam P.R.	U	6	2	U			158	193	89	102	25	5	
V.I.	Ü			Ü			2	22	-	102	20	9	
Amer. Samos	-							1	3	3			
C.N.M.L	U		-	U			3	1	13	16			

U: Unavailable -: no reported cases

TABLE III. Deaths in 121 U.S. cities,* week ending July 29, 1995 (30th Week)

Banasian Ases		III Cau	ses, By	Age (Y	ears)		PM ¹			ill Cau	ses, By	Age (Y	ears)		P&I
Reporting Area	All Ages	265	45-64	25-44	1-24	<1	Total	Reporting Area	Ali Ages	≥85	45-64	25-44	1-24	<1	Tota
EW ENGLAND	584	406	94	47	8 3	16	33	S. ATLANTIC	980	594 100	214	110	34	27	44
loston, Mass.	136	87	24	16	3	6	8	Atlanta, Ga.	185	100	38	25	-	7	5
Bridgeport, Conn. Cembridge, Mass.	33 18	18	6	1			2	Baltimore, Md.	134	66	32	23	6	1	6
all River, Mass.	34	30	1	2	1		- 11	Charlotte, N.C. Jacksonville, Fla.	121	32 87	19	10	3 4	2	3
fartford, Conn.	57	36	13	4		4	:	Miami, Fla.	Ü	ű	Ü	Ü	ũ	Ü	ű
owell, Mass.	28	22	5	1			3	Norfolk, Va.	40	31	14	3		1	- 6
ynn, Mass.	16	. 6	5	-	*		1	Richmond, Va.	88	52	16	13	5	2	5
lew Bedford, Mass	. 22	18	2	2	-		1	Sevennah, Ga.	35	24	6	4	1	-	5
lew Haven, Conn. Providence, R.I.	38 65	27 43	11	5	1	2	3	St. Petersburg, Fla.	147	33 97	32	8	7	2	11
Somerville, Mass.	4	3	1			-	3	Tampa, Fla. Washington, D.C.	127	67	34	15	5	6	1
pringfield, Mass.	43	30	5		2		3	Wilmington, Del.	17	5	6	4	2		
Waterbury, Conn.	24	20	3	1	-		1			-	_				
Vorcester, Mass.	66	62	12	2	-	*	7	E.S. CENTRAL	777	496	162	60	36	15	64
AID. ATLANTIC	2.637	1,683	543	301	60	43	116	Birmingham, Ala. Chattanooga, Tenn.	141	81 45	29	12	14	3	5
libany, N.Y.	41	29	7	3	2		3	Knoxville, Tenn.	63	48	9	3	2	i	4
Illentown, Pa.	27	22	4	1				Lexington, Ky.	53	32	10	1	3	1	7
luffalo, N.Y.	104	74	17	10	2	1	4	Memphis, Tenn.	186	114	48	16	7	1	20
amden, N.J.	29	14	11	2	1	1	1	Mobile, Ala.	77	53	14	7	1	2	10
lizabeth, N.J.	23	13	3	6	1	*	-	Montgomery, Ala.	52	35	11	4	1	1	
rie, Pa.\$	42	33	6	3	0	-	3	Nashville, Tenn.	138	88	30	13	5	2	14
ersey City, N.J. lew York City, N.Y.	1,304	27 784	287	186	32	15	32	W.S. CENTRAL	1,397	901	271	145	51	29	6
lewerk, N.J.	67	24	21	15	4	3	6	Austin, Tex.	78	50	20	7	1		
aterson, N.J.	31	14	6	1	1	2	2	Baton Rouge, La. Corpus Christi, Tex.	35	25	3	7			
hiladelphia, Pa.	500	323	109	48	11	9	34	Corpus Christi, Tex.	U	U	U	U	U	U	1
ittsburgh, Pa.5	46	36	7	1		2	1	Dellas, Tex.	171	96	35	28	8	3	
seding, Pa.	21	12	- 6	1	2	19	.1	El Paso, Tex. Ft. Worth, Tex.	101	40	16 17	- 4	7	3	
ochester, N.Y.	130	96	20	4	3	5	13	Houston, Tex.	368	227	69	41	19	12	2
chenectady, N.Y.	26	21		1		i	1	Little Rock, Ark.	39	33	4	2	10	12	-
cranton, Pa.5 yracuse, N.Y.	33 102	28 84		5		1	9	New Orleans, La.	185	117	36	26	3	3	
renton, N.J.	26	19		1	-	i	1	San Antonio, Tex.	213	146	40	17	8	2	1
Itica, N.Y.	13	10		2				Shreveport, La.	43	29	10	3	1		-
brikers, N.Y.	26			3	1		4	Tulsa, Okla.	98	69	21	4	3	1	
.N. CENTRAL	1,994			190	59	55	97	MOUNTAIN	825 100	513		96	45	16	4
kron, Ohio	50	39	8	2	1			Albuquerque, N.M. Colo. Springs, Colo		55 25	25	11	8 2	1 2	
anton, Ohio	30 418			1	-	-	1	Denver, Colo.	119	81	18	14	2	4	1
hicago, III. Incinnati, Ohio	144			52 11	15	18	28	Las Vegas, Nev.	155	93	33	15	10	3	,
leveland, Ohio	166			17	5	6	5	Ogden, Utah	12	7	3	2			
olumbus, Ohio	164			11	6	4		Phoenix, Ariz.	193	110	38	33	10	2	1
layton, Ohio	113	86	32	12	3		7	Pueblo, Colo.	14	12	2		-		
etroit, Mich.	201		34	34	13			Salt Lake City, Utah	85	48		11	6	2	
vansville, Ind.	39			2			4	Tucson, Ariz.	111	-	-	_	7	2	
ort Wayne, Ind.	56			5	5		4	PACIFIC	1,624	1,077	278	180	53	33	1
ary, Ind. rand Rapids, Mic	27 h. 62			3	3			Berkeley, Calif.	13		3	.1		1	
rand Rapids, Mic Idianapolis, Ind.	111			9	2	3 4 U 2 2	8 7	Freeno, Calif.	83	51		10	3	6	
ladison, Wis.	U			ű	2	ű	ú	Glendale, Calif.	30			2	i	1	
lilwaukee, Wis.	142					2	6	Honolulu, Hawaii	77 81	57		5	2	4	
eoris, III.	54	36	9	4		2	3	Los Angeles, Calif.	415			57	19	3	
ockford, III.	41							Pasadena, Calif.	26			3	1	1	
outh Bend, Ind.	37			2	1	1	1	Portland, Oreg.	144	103	24	14		3	
oledo, Ohio	87				2	4		Sacramento, Calif.	U	L	U	U	U	Ü	
oungstown, Ohio	50	36	7	-	1		2	San Diego, Calif.	143		17	23	8	5	
I.N. CENTRAL	662				13	23	36	San Francisco, Cali	f. 130	62	34	28	4	2	
les Moines, Iowa	76	5	1 17	5		3	4	San Jose, Calif.	163			11	2	3	
Juluth, Minn.	27			1				Senta Cruz, Celif. Seettle, Wash.	143		10	20	5	4	
anses City, Kans.	L		U		U	U	U	Spokene, Wash.	50			20	9	4	
ansas City, Mo.	12	6	24		2	3		Tacoma, Wash.	93			2	5		
incoln, Nebr.	. 13		5 27		4		1		-				-	-	
Ainnespolis, Minn Imaha, Nebr.	. 13	8	7 27		1	- 1		TOTAL	11,480	7,390	2,216	1,173	359	257	- 6
St. Louis, Mo.	12		3 20		6										
St. Paul, Minn.	50		1 0		1	1									
Wichita, Kans.	ī				Ü			1							

^{*}Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

Procurrence and influenza.
*Bacause of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
*Total includes unknown ages.
U: Unavailable -: no reported cases

Chancroid - Continued

TABLE 1. Etiology of genital ulcers among patients examined at the Mississippi State Department of Health sexually transmitted disease clinic — Jackson, Mississippi, October 20, 1994–February 1, 1995*

Etiology by PCR	No.	(%)
Single infection		
Haemophilus ducreyi	33	(41)
Treponema pallidum	8	(10)
Herpes simplex virus (HSV)	18	(22)
Multiple infections		
H. ducreyi, T. pallidum	7	(9)
T. pallidum, HSV	2	(2)
H. ducreyi, T. pallidum, and HSV	1	(1)
Other		
No etiology identified	12	(15)
Total	81	(100)

^{*}All specimens were analyzed at an independent laboratory using a research prototype multiplex polymerase chain reaction (PCR) assay that can amplify and subsequently detect DNA from H. ducreyi, Treponema pallidum, and herpes simplex virus (HSV) from a single swab specimen (3).

Editorial Note: In the United States, *H. ducreyi* accounts for a small proportion of genital ulcers. Although the number of reported cases of chancroid has decreased every year since 1987, cases are still reported from some large urban areas. In 1994, a total of 773 cases of chancroid were reported to CDC, including 357 from New York City, 201 from New Orleans, 38 from Houston, and 36 from Chicago (CDC, unpublished data, 1995). The investigation in Jackson, Mississippi, suggests that a substantially greater number of cases of chancroid occur than are reported. Based on sensitive PCR testing, approximately half the cases of genital ulcers were found to involve chancroid. Because chancroid is difficult to diagnose by clinical and tradition- all laboratory means, it probably is underdiagnosed and undertreated in many set-tings (1).

Identification of chancroid is particularly important because it is the STD most strongly associated with an increased risk for HIV transmission (4,5). Without proper treatment, ulcers require longer periods to heal, thereby prolonging for patients their susceptibility to or risk for HIV transmission or acquisition.

Chancroid should be considered in the differential diagnosis of genital ulcers. Clinicians who suspect chancroid should confirm the diagnosis by culture. Assistance can be obtained from state and territorial public health laboratories or STD programs, which also can contact CDC's Division of Sexually Transmitted Diseases Laboratory Research, National Center for Infectious Diseases (fax [404] 639-3976), or Epidemiology and Surveillance Branch, Division of Sexually Transmitted Disease Prevention, National Center for Prevention Services (fax [404] 639-8610). In communities in which the prevalence of chancroid is high, patients with genital ulcers should be treated presumptively for both chancroid and syphilis, as recommended in the 1993 Sexually Transmitted Diseases Treatment Guidelines (6).

Syphilis and genital herpes, the two most common ulcerative STDs in the United States, also have been associated with an increased risk for HIV infection (7). In Jackson, a high proportion of all patients with genital ulcers tested positive for HIV

Chancroid — Continued

antibodies. This finding underscores the need for health-care personnel in other areas to evaluate the occurrence of HIV infection among patients with genital ulcers and to target HIV-prevention services toward persons and populations with or at risk for ulcerative STDs.

References

- Schulte JM, Martich FA, Schmid GP. Chancroid in the United States, 1981–1970: evidence for underreporting of cases. MMWR 1992;41(no. SS-3):57–61.
- 2. Morse SA. Chancroid and Haemophilus ducrevi. Clin Microbiol Rev 1989:2:137-57.
- Orle KA, Martin DH, Gates CA, Johnson SR, Morse SA, Weiss JB. Multiplex PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex viruses types -1 and -2, from genital ulcers [Abstract no. C-437]. In: Abstracts of the 94th general meeting of the American Society for Microbiology. Washington, DC: American Society for Microbiology, 1994.
- Jessamine PG, Plummer FA, Achola JON, et al. Human immunodeficiency virus, genital ulcers, and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis 1990;69(suppl):181–6.
- Telzak EE, Chiasson MA, Bevier PJ, Stoneburner RL, Castro KG, Jaffe HW. HIV-1 seroconversion in patients with and without genital ulcer disease. Ann Intern Med 1993;119:1181–6.
- 6. CDC. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993;42(no. RR-14).
- Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;19:61–77.

Notice to Readers

Update: Recommendations to Prevent Hepatitis B Virus Transmission — United States

In October 1994, the Advisory Committee on Immunization Practices (ACIP) approved recommendations expanding the vaccination strategy to eliminate hepatitis B virus (HBV) transmission in the United States. These recommendations include:

- Vaccination of all unvaccinated children aged <11 years who are Pacific Islanders or who reside in households of first-generation immigrants from countries where HBV is of high or intermediate endemicity.
- Vaccination of all 11–12-year-old children who have not previously received hepatitis B vaccine.

Reported by: Epidemiology and Surveillance Div, National Immunization Program; Hepatitis Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

Editorial Note: In November 1991, the ACIP recommended that hepatitis B vaccine be integrated into infant vaccination schedules (1). However, high rates of HBV infection continue to occur among children aged 0–10 years who are Alaskan Natives, Pacific Islanders, and infants of first-generation immigrant mothers from areas where HBV infection is of high or intermediate endemicity. Among children in these populations, the prevalence of chronic HBV infection ranges from 2%–5%, and infection rates average 2% per year (2,3). These infections occur in children born to women who are hepatitis B surface antigen-negative and account for a large proportion of the chronic HBV infections that occur each year in the United States. Of the estimated 1 million Asian and Pacific Islander children aged 2–10 years in the United States, <10% have received hepatitis B vaccine. Special efforts should be made to ensure hepatitis B vaccination of these populations because of their high risk for chronic HBV infection and death from HBV-related chronic liver disease.

Notices to Readers - Continued

Routine infant hepatitis B vaccination is the most effective means to prevent HBV transmission in the United States. The effect of routine infant vaccination on acute disease incidence may not be apparent for 20–30 years because currently most infections occur among young adults. Vaccination of previously unvaccinated children at age 11–12 years should result in a more rapid decline in the incidence of HBV infection. However, adolescent hepatitis B vaccination should not supplant vaccination of infants, because routine infant hepatitis B vaccination would eventually eliminate the need for adolescent and adult vaccination.

Vaccination recommendations are most effective when they become integrated into routine health care. Although preventive health services and vaccination visits for adolescents are not well established in the United States, hepatitis B vaccination of this age group has been successful in settings including schools and clinical practices (4,5). The ACIP has recommended that hepatitis B vaccination of adolescents be done as part of a routine adolescent vaccination visit at age 11–12 years. This visit should be used to ensure that all adolescents have received three doses of hepatitis B vaccine, two doses of measles-mumps-rubella vaccine, a booster dose of tetanus and diphtheria toxoids, and to assess whether adolescents are immune to varicella. The establishment of an adolescent vaccination visit provides the opportunity to deliver preventive health-care services to this underserved population.

References

- Mahoney FJ, Lawrence M, Scott K, Le Q, Lambert S, Farley T. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics (in press).
- Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269–73.
- CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination—recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(no. RR-13).
- CDC. Hepatitis B vaccination of adolescents—California, Louisiana, and Oregon, 1992–1994.
 MMWR 1994;43:605–9.
- Kollar LM, Rosenthal SL, Biro FM. Hepatitis B vaccine series compliance in adolescents. Pediatr Infect Dis J 1994;13:1006–8.

Notice to Readers

Availability of Applications for Public Health Leadership Institute

The CDC/University of California Public Health Leadership Institute (PHLI) is a 1-year scholars' program that includes an intensive on-site week, scheduled for March 18–23, 1996. The PHLI is conducted under a cooperative agreement between CDC's Public Health Practice Program Office and the University of California at Los Angeles. The fifth year of the PHLI will begin on October 30, 1995, with an orientation for scholars at the American Public Health Association annual meeting in San Diego.

Senior state, local, and international health officials, including deputy directors nominated by state health directors, are eligible. Applications must be submitted by August 31, 1995. Selected scholars will be notified by September 25, 1995. Additional information and applications are available from the Director, PHLI, telephone (510) 649-1599.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to lists@list.cdc.gov. The body content should read subscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 783-3238.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (404) 332-4555.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention David Satcher, M.D., Ph.D. Deputy Director, Centers for Disease Control and Prevention

Claire V. Broome, M.D. Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc. Editor, MMWR Series

DUNCS

ZORHO HKN POLA SONO 0-1 HO RIDHW 040 SNO

MAZHN 033 10 S

S P

Z Nm

Richard A. Goodman, M.D., M.P.H. Managing Editor, MMWR (weekly) Karen L. Foster, M.A.

Writers-Editors, MMWR (weekly) David C. Johnson

Darlene D. Rumph-Person Caran R. Wilbanks

☆U.S. Government Printing Office: 1995-633-175/27001 Region IV

LsJ HMCZO MHH 0000m4 ROTE ROTE

Centers for Disease Control Public Health Service **HEALTH AND HUMAN SERVICES** DEPARTMENT OF and Prevention (CDC) Georgia 30333

Penalty for Private Use \$300

OSTAGE & FEES FIRST-CLASS ermit No. G-28 PHS/CDC MAR

HHS Publication No. (CDC) 95-8017

Redistribution using permit imprint is illegal.

